Triple-negative breast cancer (TNBC) gets its name from the fact that it is not driven by breast cancer’s three major molecular markers—estrogen receptor, progesterone receptor, and the HER2 oncogene—that classify breast cancer subtypes, making it untreatable with hormone- or HER2-directed therap
You are here
The Progress Report Progress never stops. Stay informed with the latest news on breast cancer research, treatment, and prevention.
Tag:
SABCS 2020 x
At this year’s virtual San Antonio Breast Cancer Symposium (SABCS)—the world’s largest scientific conference dedicated to breast cancer—investigators reported a number of key findings from trials testing immunotherapies and targeted agents for triple-negative breast cancer (TNBC), an aggressive f
Ductal carcinoma in situ (DCIS), also called stage 0 breast cancer, is a noninvasive precursor of breast cancer. The term “in situ” means “in place,” so named because it has not spread from the duct into the surrounding breast tissue. About 60,000 people are diagnosed with DCIS in the U.S.
Up to 45 percent of patients with metastatic breast cancer develop brain metastases, and those who do have an average survival of three to 23 months.
Across the spectrum of breast cancer care, racial and ethnic disparities remain a persistent challenge.
Three BCRF investigators were honored at this year’s San Antonio Breast Cancer Symposium (SABCS), the largest conference dedicated to breast cancer in the world.
A groundbreaking, BCRF-supported phase III clinical trial, RxPONDER, has just demonstrated that some women with a common type of breast cancer can forgo chemotherapy and be successfully treated with hormone therapy alone.